Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Therapy with Tislelizumab for High Risk Metastatic Prostate Cancer
NCT05189457Phase 2Active, not recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Jan 2022
- Primary completion
- Jul 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in prostate cancer (PCa), sponsored by Moffitt Cancer Center. Started Jan 2022; status: active, not recruiting.
02
Drugs
tislelizumab
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05189457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05189457.